CORDA Investment Management LLC. Purchases 5,162 Shares of Pfizer Inc. (NYSE:PFE)

CORDA Investment Management LLC. boosted its position in Pfizer Inc. (NYSE:PFE) by 0.5% in the 4th quarter, Holdings Channel reports. The firm owned 1,016,016 shares of the biopharmaceutical company’s stock after buying an additional 5,162 shares during the quarter. Pfizer accounts for approximately 2.2% of CORDA Investment Management LLC.’s portfolio, making the stock its 23rd biggest position. CORDA Investment Management LLC.’s holdings in Pfizer were worth $26,955,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Swedbank AB grew its position in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the last quarter. Pallas Capital Advisors LLC grew its holdings in shares of Pfizer by 54.8% in the third quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after purchasing an additional 9,102 shares during the last quarter. Fidelis Capital Partners LLC grew its holdings in shares of Pfizer by 5.2% in the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock worth $746,000 after purchasing an additional 1,267 shares during the last quarter. Great Diamond Partners LLC purchased a new position in Pfizer in the 3rd quarter worth about $203,000. Finally, First Trust Direct Indexing L.P. lifted its holdings in Pfizer by 15.4% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 82,585 shares of the biopharmaceutical company’s stock valued at $2,390,000 after buying an additional 11,026 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.3 %

Shares of Pfizer stock opened at $26.09 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $147.83 billion, a P/E ratio of 18.50, a PEG ratio of 0.64 and a beta of 0.64. The firm’s 50 day moving average price is $26.35 and its 200-day moving average price is $27.35. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.